PHAXIAM Therapeutics (XPAR:PHXM) EBIT: €-3.32 Mil (TTM As of Sep. 2023)

What is PHAXIAM Therapeutics EBIT?

PHAXIAM Therapeutics XPAR:PHXM 38 EBIT is €-3.32 Mil as of Sep. 2023. GuruFocus rates XPAR:PHXM with a GF Score™ of 38/100.

PHAXIAM Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was €-5.38 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was €-3.32 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PHAXIAM Therapeutics's annualized ROC % for the quarter that ended in Sep. 2023 was -58.65%. PHAXIAM Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -566.24%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PHAXIAM Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 15.97%.

PHAXIAM Therapeutics (XPAR:PHXM) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PHAXIAM Therapeutics's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	-23.028 * ( 1 - 0% )	/	( (39.265	+	0)	/ 1 )
=	-23.028	/	39.265
=	-58.65 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	65.531	-	12.734	-	( 25.189	-	max(0, 17.39	-	30.922	+	25.189	))
=	39.265

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

PHAXIAM Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-21.5	/	( ( (3.797 + max(-14.683, 0))	+	(0 + max(0, 0)) )	/	1 )
=	-21.5	/	( ( 3.797	+	0 )	/	1 )
=	-21.5	/	3.797
=	-566.24 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.245	+	0	+	1.634)	-	(12.734	+	0.42	+	3.408)
=	-14.683

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0	+	0	+	0)
=	0

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PHAXIAM Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2023 )
	=	-3.32	/	-20.792
	=	15.97 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PHAXIAM Therapeutics EBIT Related Terms

PHAXIAM Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for PHAXIAM Therapeutics's EBIT can be seen below:

PHAXIAM Therapeutics EBIT Chart

PHAXIAM Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

-38.21

-62.17

-71.14

-51.66

0.61

PHAXIAM Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23
EBIT	Get a 7-Day Free Trial															14.66	-4.43	2.06	0.00	-5.38

XPAR:PHXM vs VRTX, REGN, SGEN: EBIT Comparison

For the Biotechnology subindustry, PHAXIAM Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PHAXIAM Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PHAXIAM Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PHAXIAM Therapeutics's EV-to-EBIT falls into.

Save Embed

38GF Score

PHAXIAM Therapeutics SA XPAR:PHXM

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

PHAXIAM Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.32 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of €-3.32 Mil mean?

PHAXIAM Therapeutics (XPAR:PHXM) has a EBIT of €-3.32 Mil as of Sep. 2023. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PHAXIAM Therapeutics.

Is PHAXIAM Therapeutics' EBIT too high?

PHAXIAM Therapeutics' current EBIT is €-3.32 Mil. Overall, PHAXIAM Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.

How does PHAXIAM Therapeutics' EBIT compare to VRTX and REGN?

PHAXIAM Therapeutics' EBIT of €-3.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PHAXIAM Therapeutics. PHAXIAM Therapeutics's current EBIT is €-3.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is PHAXIAM Therapeutics stock overvalued right now?

PHAXIAM Therapeutics (XPAR:PHXM) has a current EBIT of €-3.32 Mil. The current EBIT is €-3.32 Mil. PHAXIAM Therapeutics' overall GF Score™ is 38/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For PHAXIAM Therapeutics (XPAR:PHXM), the current EBIT is €-3.32 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PHAXIAM Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies XPAR:ALVIO XPAR:GNRO XPAR:ALGEN XPAR:ALDVI XPAR:SIGHT XPAR:ALCOX XPAR:ABNX XPAR:POXEL XPAR:FALG XPAR:ALHYG OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Address 60 Avenue Rockefeller, Lyon, FRA, 69008

Website https://www.phaxiam.com

PHAXIAM Therapeutics SA is a clinical-stage biopharmaceutical company developing therapies for severe forms of cancer and orphan diseases. Its platform uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its product candidate eryaspase, also referred to as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple-negative breast cancer, or TNBC.

38GF Score

Get the complete analysis for XPAR:PHXM

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.10

Price

View XPAR:PHXM Analysis

See EBIT data for all stocks →